Zimmer Partners’s Akero Therapeutics AKRO Stock Holding History

Zimmer Partners’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-25,000	Closed	-$479K	–	107
2019 Q2	$479K	Buy	+25,000	New	+$474K	0.01%	99

Other funds holding AKRO

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Zimmer Partners's AKRO Position: Q3 2019 in Review

Zimmer Partners sold out of Akero Therapeutics (AKRO) in Q3 2019, closing a stake of 25,000 shares — an estimated $479K sold.

Zimmer Partners first reported a position in AKRO in Q2 2019 and held it in 1 quarter. The position peaked at $479K in Q2 2019. 54 funds tracked by Wall St. Rank hold AKRO as of Q3 2019.

Zimmer Partners reported no remaining Akero Therapeutics position as of Q3 2019 after selling out during the quarter.
Zimmer Partners sold 25,000 Akero Therapeutics shares in Q3 2019, an estimated $479K.
Zimmer Partners first reported a position in Akero Therapeutics in Q2 2019 and held it in 1 quarter.
Zimmer Partners's Akero Therapeutics position peaked at $479K in Q2 2019.
54 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2019.

Based on Zimmer Partners's 13F filing for Q3 2019, filed 14 Nov 2019.